%0 Journal Article
%T The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)¡ªA Novel Anticancer Compound
%A Yuqing Huang
%A Zaiyou Tan
%A Lin Luo
%A Hui Yang
%A Chunmei Tong
%A Wenfei Chen
%A Tingyu Huang
%A Ruiling Liu
%J Journal of Crystallization Process and Technology
%P 27-30
%@ 2161-7686
%D 2014
%I Scientific Research Publishing
%R 10.4236/jcpt.2014.41004
%X <p>
	<span>Objective: To determine the transformation between two known crystal
forms of the title compound (C<sub>18</sub>H<sub>23</sub>NO<sub>3</sub>, Mr</span><span> </span><span>= 301.37). Methods: To recrystallize or heat the crystals and determine
the crystal form by testing the melting points. Results: Both the two known
crystal forms of the title compound can be changed by dissolving into different
organic solvents such as acetone and ethyl acetate. Crystal form I</span><span> </span><span>was not influenced by heating while crystal form II</span><span style=\"font-family:ËÎÌå;\"> </span><span>can be transformed to crystal form I</span><span> </span><span>through melting method. Conclusion: Organic solvents have significant
influences on the two crystal forms of title compound. Crystal form I</span><span> </span><span>shows a better thermal stability than crystal form II</span><span>.</span> 
</p>
%K SU2162
%K Polymorphism
%K Crystal Form
%K Melting Method
%K Solvent Method
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=41735